MedPath
NMPA Approval

Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets

国药准字HJ20220081

October 18, 2022

Drug Information

多替拉韦利匹韦林片

片剂

每片含50mg 多替拉韦钠(按多替拉韦计)和25mg 盐酸利匹韦林(按利匹韦林计)

化学药品

October 18, 2022

October 17, 2027

Company Information

Applicant Company

ViiV Healthcare BV

Van Asch van Wijckstraat 55H,3811 LP Amersfoort, Netherlands

Manufacturing Company

glaxo operations (uk) ltd.(trading as glaxo wellcome operations)

Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

多替拉韦利匹韦林片 - NMPA 批准文号 | MedPath